|
Parameters
|
HC
|
Metformin (months)
|
Rosiglitazone (months)
|
|---|
| | |
0
|
1
|
2
|
0
|
2
|
|---|
|
WBC × 10
9
|
6.7 ± 0.1
|
7.3 ± 0.3b
|
7.4 ± 0.4
|
7.5 ± 0.2
|
7.04 ± 0.5b
|
6.8 ± 0.6
|
|
PMNLs × 10
9
|
4.0 ± 0.1
|
4.6 ± 0.3b
|
4.7 ± 0.2
|
4.9 ± 0.1
|
4.2 ± 0.4b
|
4.4 ± 0.5
|
|
PMNL apoptosis (%)
|
4.0 ± 0.1
|
12.7 ± 3.4b
|
9.5 ± 2.8a, b
|
6.5 ± 1.0a
|
20.4 ± 4.4b
|
7.5 ± 1.9a
|
|
Monocytes × 10
9
|
0.36 ± 0.02
|
0.44 ± 0.05b
|
0.40 ± 0.04b
|
0.39 ± 0.04a
|
0.49 ± 0.03b
|
0.39 ± 0.01a
|
|
Fibrinogen (mg/dl)
|
304.6 ± 17.6
|
440.1 ± 25.2b
|
471.1 ± 28.8b
|
415.9 ± 41.2a, b
|
400 ± 16.6b
|
332.8 ± 8.1a,b
|
|
Albumin (g/dl)
|
4.6 ± 0.05
|
4.53 ± 0.1
|
4.74 ± 0.1
|
4.7 ± 0.04
|
4.5 ± 0.1
|
4.6 ± 0.1
|
|
Transferrin (g/dl)
|
273.2 ± 10.6
|
274.6 ± 8.4
|
276.7 ± 7.2
|
287.9 ± 7.7
|
264.7 ± 7.6
|
286.2 ± 8.9
|
|
CRP (mg/L)
|
1.5 ± 0.1
|
8.3 ± 1.6b
|
6.6 ± 1.1b
|
5.8 ± 1.5a, b
|
4.3 ± 0.9b
|
1.8 ± 0.2a,b
|
- a P < 0.05, treated DM patients vs. untreated DM patients;
- b P < 0.05, untreated DM patients vs. HC subjects
